A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...

Physical AI holds the promise of making everything from robots to a slew of mobile edge devices much more interactive and useful, but it will significantly alter how systems are designed, verified, ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA has granted fast track designation to its experimental therapy TEV-56286 (emrusolmin) for treating Multiple System Atrophy. Emrusolmin, ...

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...

Sara’s Ride, an event honoring the life of Bear Valley resident Sara Nilson, who died in 2023 from the rare neurodegenerative disorder multiple system atrophy, or MSA, will be held Sept. 13 in Bear ...

Fans of the Sony PlayStation and its excellent Dualsense controller have some new features to explore in a beta update. If Microsoft wants "Everything to be an Xbox," Sony also wants its DualSense ...